Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQB3702 plus immunochemotherapy in B-cell lymphoma
CTR20243103Phase 2Suspended
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3702 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Nov 2024; status: suspended.
02
Drugs
TQB3702
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20243103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243103.